GenSpera
American biotechnology company
GenSpera, Inc. is an American biotechnology company focused on the development of innovative cancer therapeutics. The company is known for its pioneering work in the field of prodrugs, which are designed to be activated specifically within the tumor microenvironment, thereby minimizing damage to healthy tissues.
History[edit | edit source]
GenSpera was founded with the mission to revolutionize cancer treatment by developing targeted therapies that exploit the unique characteristics of tumor cells. The company has its roots in the research of Dr. John Isaacs and Dr. Samuel Denmeade, who were instrumental in the development of the company's lead compound, G-202.
Technology[edit | edit source]
GenSpera's technology platform is based on the concept of prodrugs, which are inactive compounds that become active only in the presence of specific enzymes found in tumor cells. This approach allows for the selective targeting of cancer cells, reducing the side effects commonly associated with traditional chemotherapy.
Prodrug Activation[edit | edit source]
The company's lead compound, G-202, is a prodrug that is activated by the enzyme prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells and the blood vessels of many other solid tumors. Once activated, G-202 releases a potent cytotoxin that disrupts the tumor's blood supply, leading to cancer cell death.
Pipeline[edit | edit source]
GenSpera's pipeline includes several other prodrug candidates in various stages of development. These candidates are designed to target different types of cancer, including hepatocellular carcinoma, glioblastoma, and other solid tumors.
Clinical Trials[edit | edit source]
The company has conducted multiple clinical trials to evaluate the safety and efficacy of its lead compound, G-202. These trials have demonstrated promising results, with significant tumor reduction observed in patients with advanced cancers.
Partnerships and Collaborations[edit | edit source]
GenSpera collaborates with leading academic institutions and research organizations to advance its drug development programs. These partnerships are crucial for the company's efforts to bring new cancer therapies to market.
Future Directions[edit | edit source]
Looking ahead, GenSpera aims to expand its pipeline and explore new indications for its prodrug technology. The company is committed to improving the lives of cancer patients through innovative and targeted treatment options.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
